Novartis drops post-MI development of Tekturna on Phase II failure
This article was originally published in Scrip
Executive Summary
Novartis's first-in-class direct renin inhibitor antihypertensive Tekturna (aliskiren) failed to reduce heart remodelling when used as a post-myocardial infarction (MI) treatment, show Phase II results presented at the American College of Cardiology (ACC) in Atlanta this week. Novartis has decided to terminate post-MI development of Tekturna and focus on more advanced trials for other indications.